AZTA logo

Azenta, Inc. Stock Price

NasdaqGS:AZTA Community·US$1.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

AZTA Share Price Performance

US$25.36
-8.11 (-24.23%)
US$26.20
Fair Value
US$25.36
-8.11 (-24.23%)
3.2% undervalued intrinsic discount
US$26.20
Fair Value
Price US$25.36
AnalystConsensusTarget US$26.20
AnalystHighTarget US$45.00
AnalystLowTarget US$20.00

AZTA Community Narratives

·
Fair Value US$26.2 3.2% undervalued intrinsic discount

AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
·
Fair Value US$45 43.6% undervalued intrinsic discount

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$20 26.8% overvalued intrinsic discount

Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$45
43.6% undervalued intrinsic discount
Revenue
6.71% p.a.
Profit Margin
6.78%
Future PE
54.34x
Price in 2029
US$56.76

Trending Discussion

Updated Narratives

AZTA logo

AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns

Fair Value: US$20 26.8% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZTA logo

AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery

Fair Value: US$26.2 3.2% undervalued intrinsic discount
3 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
AZTA logo

Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift

Fair Value: US$45 43.6% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Flawless balance sheet and good value.

0 Risks
3 Rewards

Azenta, Inc. Key Details

US$596.5m

Revenue

US$332.1m

Cost of Revenue

US$264.4m

Gross Profit

US$375.3m

Other Expenses

-US$110.9m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-2.41
44.33%
-18.59%
0%
View Full Analysis

About AZTA

Founded
1978
Employees
2900
CEO
John P. Marotta
WebsiteView website
www.azenta.com

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

Recent AZTA News & Updates

Narrative Update Jul 07

AZTA: Future P/E Compression And Impairment Charges Will Pressure Returns

Analysts have reduced their price target for Azenta from $30 to $20, citing updated assumptions that include a slightly higher discount rate, more modest revenue growth expectations, a marginally revised profit margin outlook, and a lower future P/E estimate. What’s in the News for Azenta Azenta, Inc.
Narrative Update Jun 23

AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery

The latest Narrative Update on Azenta reflects a lower analyst price target, with recent Street research trimming estimates by $5 to $10 as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Azenta points to a more cautious stance on valuation, with reduced price targets reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.

Recent updates

No updates